Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 2, 2016, Pages 172-180

  Kerzerho, Jerome ^a   McIlvaine, Elizabeth J ^b   Anthony, Patricia ^b   Mack, Wendy J ^b   Wang, Chia Hao ^b   Frederick, Toni ^b   Operskalski, Eva ^b   Chen, Zhi ^b   Al Harthi, Lena ^c   Landay, Alan ^c   Young, Mary A ^d   Tien, Phyllis C ^e   Augenbraun, Michael ^f   Strickler, Howard D ^g   Akbari, Omid ^a   Golub, Elizabeth T ^h   Sharp, Gerald B ^b   Kovacs, Andrea ^b  

^a Department of Molecular Microbiology and Immunology ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Downstate Health Sciences University   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HAART; HIV and HCV coinfection; IL 7 level

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTERLEUKIN 7; VIRUS RNA; IL7 PROTEIN, HUMAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MIXED INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; VIREMIA; VIRUS LOAD; BLOOD; COMPLICATION; HEPACIVIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; NATURAL KILLER T CELL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-7; MIDDLE AGED; NATURAL KILLER T-CELLS; PROSPECTIVE STUDIES; VIREMIA;

EID: 84955575585     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000832     Document Type: Article

References (44)

1. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8 + and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997;89: 3700-3707.
2. Margolick JB, Munoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med. 1995;1:674-680.
3. Mastroianni CM, Forcina G, d'Ettorre G, et al. Circulating levels of interleukin-7 in antiretroviral-naive and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin Trials. 2001;2:108-112.
4. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr. Opin. HIV AIDS. 2011;6:478-482.
5. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 2004;39:1507-1513.
6. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
7. Kovacs A, Al-Harthi L, Christensen S, et al. CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis. 2008;197:1402-1407.
8. Miller MF, Haley C, Koziel MJ, et al. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41:713-720.
9. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192:992-1002.
10. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206.
11. Weis N, Lindhardt BO, Kronborg G, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis. 2006;42:1481-1487.
12. Kovacs A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis. 2010;201:823-834.
13. Steffens CM, Managlia EZ, Landay A, et al. Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood. 2002;99:3310-3318.
14. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983-2990.
15. Schluns KS, Kieper WC, Jameson SC, et al. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol. 2000;1:426-432.
16. Tan JT, Dudl E, LeRoy E, et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA. 2001;98:8732-8737.
17. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol. 2007;7:144-154.
18. Laky K, Lefrancois L, von Freeden-Jeffry U, et al. The role of IL-7 in thymic and extrathymic development of TCR gamma delta cells. J Immunol. 1998;161:707-713.
19. Morrissey PJ, Conlon P, Braddy S, et al. Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J Immunol. 1991;146:1547-1552.
20. Napolitano LA, Burt TD, Bacchetti P, et al. Increased circulating interleukin-7 levels in HIV-1-infected women. J Acquir Immune Defic Syndr. 2005;40:581-584.
21. Llano A, Barretina J, Gutierrez A, et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol. 2001;75:10319-10325.
22. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7:73-79.
23. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. 2001;22:564-571.
24. Al-Harthi L, Voris J, Du W, et al. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis. 2006;193:1202-1210.
25. Korner C, Tolksdorf F, Riesner K, et al. Hepatitis C coinfection enhances sensitization of CD4(+) T-cells towards fas-induced apoptosis in viraemic and HAART-controlled HIV-1-positive patients. Antivir Ther. 2011;16:1047-1055.
26. Korner C, Kramer B, Schulte D, et al. Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. Clin Sci (Lond). 2009;116:861-870.
27. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 2005;23:877-900.
28. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med. 2005;202:1623-1626.
29. Gonzalez VD, Falconer K, Michaelsson J, et al. Expansion of CD56-NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol. 2008; 128:46-56.
30. Lange CG, Lederman MM. Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J Antimicrob Chemother. 2003;51: 1-4.
31. Beq S, Rannou MT, Fontanet A, et al. HIV infection: pre-highly active antiretroviral therapy IL-7 plasma levels correlate with long-term CD4 cell count increase after treatment. AIDS. 2004;18:563-565.
32. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antire-troviral therapy. J Acquir Immune Defic Syndr. 2003;33:365-372.
33. Lincoln D, Petoumenos K, Dore GJ; Australian HIVOD. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretro-viral therapy. HIV Med. 2003;4:241-249.
34. Macias J, Pineda JA, Lozano F, et al. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naive patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis. 2003;22:675-680.
35. Cianci R, De Luca A, Cammarota G, et al. HCV co-infection does not affect the TREC/IL-7 pathway in HIV disease. Eur Rev Med Pharmacol Sci. 2008;12:67-69.
36. Soriano-Sarabia N, Vallejo A, Molina-Pinelo S, et al. HIV-hepatitis C virus co-infection is associated with decreased plasmatic IL-7 levels. AIDS. 2007;21:253-255.
37. Allers K, Bosel D, Epple HJ, et al. Effect of age on the CD4(+) T-cell impairment in HIV-infected persons without and with cART. J Acquir Immune Defic Syndr. 2014;66:7-15.
38. Achhra AC, Zhou J, Dabis F, et al. Difference in absolute CD4+ count according to CD4 percentage between Asian and Caucasian HIV-infected patients. J AIDS Clin Res. 2010;1:1-4.
39. Anglaret X, Diagbouga S, Mortier E, et al. CD4+ T-lymphocyte counts in HIV infection: are European standards applicable to African patients? J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:361-367.
40. Mekonnen Y, Geskus RB, Hendriks JC, et al. Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers. J Infect Dis. 2005;192:739-748.
41. Staehelin C, Rickenbach M, Low N, et al. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS. 2003;17:2237-2244.
42. Giordano TP, Wright JA, Hasan MQ, et al. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis. 2003;37:433-437.
43. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006;57:4-7.
44. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183:1290-1294.